指南与共识乳腺癌放疗放疗物理与技术

基于ESTRO-ACROP乳房切除术后即刻假体重建靶区勾画指南的临床靶区与传统体积的VMAT与螺旋断层放疗剂量学评估

Dosimetric evaluation of VMAT and helical tomotherapy techniques comparing conventional volumes with clinical target volumes based on new ESTRO ACROP post-mastectomy with immediate implant reconstruction contouring guidelines.
指南 / 共识 · Radiat Oncol · 2022-10-21

本研究纳入8例左侧和8例右侧乳腺癌乳房切除术后即刻假体重建患者,基于ESTRO-ACROP共识指南勾画假体排除临床靶区(CTVp),比较螺旋断层放疗(HTp)与容积旋转调强放疗(VMATp)的剂量学差异。两种技术均获得适形均匀的CTVp剂量分布并降低假体平均剂量,HTp在降低除心脏以外危及器官剂量方面优于VMATp,但VMATp适形数更高。

要点

  • HTp与VMATp在CTVp覆盖指标PTVp-D95、PTVp-Vpres及均匀性指数上无统计学显著差异(p>0.05)。
  • VMATp适形数显著高于HTp(0.79±0.12 vs 0.69±0.15,Z=-2.17,p=0.030)。
  • HTp显著降低LAD的Dmax和Dmean及心脏V5,但两者均未能降低心脏最大和平均剂量。

核心结论

  • HTp与VMATp两种技术均能在CTVp内获得适形且均匀的剂量分布,同时降低假体平均剂量。
  • HTp在降低除心脏以外所有危及器官剂量方面优于VMATp。

研究设计与样本

  • 本研究纳入8例左侧和8例右侧乳腺癌乳房切除术后即刻假体重建患者。
  • 计划CT数据在自由呼吸下采集,患者接受针对常规CTV的HT技术治疗。
  • 回顾性基于EACG由同一放疗医师勾画CTVp,并基于CTVp生成HTp和VMATp治疗计划。
  • 每例患者从三种不同治疗计划中获取相关剂量学参数。

主要发现

  • HTp与VMATp计划在PTVp-D95、PTVp-Vpres及均匀性指数方面无统计学显著差异(p>0.05)。
  • VMATp适形数显著高于HTp(HTp vs VMATp,0.69±0.15 vs 0.79±0.12,Z=-2.17,p=0.030)。
  • HTp显著降低LAD的Dmax和Dmean(LAD-Dmax:χ2=12.25,p=0.002;LAD-Dmean:χ2=12.30,p=0.002)。
  • HTp与VMATp均未能降低心脏最大和平均剂量(p>0.05)。
  • VMATp心脏V5显著高于HTp(21.2±9.8 vs 42.7±24.8,p=0.004)。

关键数值与推荐

  • EACG推荐乳房切除术后即刻假体重建患者放疗采用假体排除临床靶区(CTVp)定义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ESTRO-ACROP Consensus Guideline (EACG) recommends implant excluded clinical target volume (CTVp) definitions for post-mastectomy radiation therapy after implant-based immediate breast reconstruction (IBR). The purpose of this study is to investigate the effectiveness of Helical Tomotherapy (HTp) and Volumetric Modulated Arc Therapy (VMATp) treatment techniques in terms of CTVp coverage and reduced organ at risk (OAR), normal tissue and implant doses when CTVp was used for treatment planning as the target structure instead of conventional CTV. METHODS: Eight left-sided and eight right-sided breast cancer patients who underwent IBR after mastectomy were included in this study. Planning CT data sets were acquired during free breathing and patients were treated with HT technique targeted to conventional CTV. Retrospectively, CTVp was delineated based on EACG by the same radiation oncologist, and treatment plans with HTp and VMATp techniques were generated based on CTVp. For each patient, relevant dosimetric parameters were obtained from three different treatment plans. RESULTS: There was no statistically significant difference on target coverage in terms of, PTVp-D95, PTVp-Vpres, homogeneity index (p > 0.05) between HTp and VMATp plans. But, the conformity numbers were significantly higher (HTp vs VMATp, 0.69 ± 0.15 vs 0.79 ± 0.12) for VMATp (Z = - 2.17, p = 0.030). While HTp significantly lowered Dmax and Dmean for LAD (LAD-Dmax: χ2 = 12.25, p = 0.002 and LAD-Dmean: χ2 = 12.30, p = 0.002), neither HTp nor VMATp could reduce maximum and mean dose to heart (p > 0.05). Furthermore, heart volume receiving 5 Gy was significantly higher for VMATp when compared to HTp (21.2 ± 9.8 vs 42.7 ± 24.8, p: 0.004). Both techniques succeeded in reducing the mean dose to implant (HTp vs HT, p < 0.001; VMATp vs HT, p < 0.001; VMATp vs HTp, p = 0.005). CONCLUSION: Both HTp and VMATp techniques succeeded to obtain conformal and homogeneous dose distributions within CTVp while reducing the mean implant dose. HTp was found to be superior to VMATp with regards to lowering all OAR doses except for CB.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Göksel EO, Tezcanli E, Arifoğlu A, et al. Dosimetric evaluation of VMAT and helical tomotherapy techniques comparing conventional volumes with clinical target volumes based on new ESTRO ACROP post-mastectomy with immediate implant reconstruction contouring guidelines. Radiat Oncol. 2022. PMID: 36271401. doi:10.1186/s13014-022-02134-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。